Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genzyme Nabs Elusive Lemtrada Approval, But As Third-Line MS Therapy

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA says therapy for relapsing multiple sclerosis should be reserved for patients who fail two or more other MS treatments; REMS includes four-year follow up.

You may also be interested in...



ECTRIMS 2016: Alemtuzumab Benefits Continue Six Years Post-Treatment

The continuing benefits of Sanofi’s multiple sclerosis therapy Lemtrada six years after two short courses bolster the case for its use early in the course of the disease.

Genzyme Will Appeal Lemtrada “Complete Response” After FDA Seeks More Trials

Rater-blinded design for multiple sclerosis claim netted an approval in Europe but a rejection by FDA, which was concerned about bias related to open label studies.

Sanofi/Genzyme Primed Patient Community For Campath’s Removal From Commercial Distribution

As Sanofi/Genzyme plans to take leukemia drug Campath out of the commercial market in the U.S. and Europe so it will not undercut sales of the same compound in a different indication, patient advocates are confident that a patient-access system will continue providing the drug to those who need it.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS076643

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel